FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206788435> ?p ?o ?g. }

• W3206788435 endingPage "516.e6" @default.
• W3206788435 startingPage "506" @default.
• W3206788435 abstract "Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) comprises the triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and intolerance to inhibitors of the cyclooxygenase-1 enzyme. The impact of omalizumab on prevention of aspirin-induced hypersensitivity in N-ERD patients with and without atopic sensitization has not been thoroughly addressed.To investigate the effect of omalizumab treatment on aspirin tolerance in atopic and nonatopic N-ERD patients.This single-center, prospective trial evaluated overall omalizumab-induced aspirin tolerability in N-ERD patients by performing aspirin challenge testing before and after 6 months of anti-immunoglobulin E (IgE) therapy. The impact of omalizumab on CRSwNP asthma as well as serum and tissue biomarkers in patients with and without comorbid atopic sensitizations was further analyzed.Out of 33 patients included in the study, 56% developed complete aspirin tolerance and 18% tolerated higher dosages after 24 weeks. Polyp size and disease-specific symptoms (nasal polyp score [NPS] -1.9 ± 0.3, P < .001; Sino-Nasal Outcome Test [SNOT]-20 -16.7 ± 3.7, P < .001; Asthma Control Test [ACT] 3.2 ± 0.7, P < .001) improved in all patients irrespective of atopic sensitization. Effectiveness of omalizumab was accompanied by an increase in mean total serum IgE (307.8 ± 42 kU/L; P < .001) and a decrease in eosinophilic cationic protein (-10.6 ± 6.7 μg/L) and in relative eosinophilia (-2.5 ± 0.7%; P < .01). Whereas there was a significant reduction of tissue IgE (P < .05) in all patients after 4 weeks, the number of local eosinophils decreased only in atopic individuals (P < .05).Omalizumab induced complete aspirin tolerance in the majority of patients (56%) independent of atopic sensitization and demonstrated clinical efficacy in the treatment of CRSwNP and asthma. Inhibition of IgE can therefore be a promising treatment option in preventing NSAID hypersensitivity reactions in N-ERD patients." @default.
• W3206788435 created "2021-10-25" @default.
• W3206788435 creator A5001448895 @default.
• W3206788435 creator A5013554446 @default.
• W3206788435 creator A5017906399 @default.
• W3206788435 creator A5025436509 @default.
• W3206788435 creator A5027654158 @default.
• W3206788435 creator A5053402932 @default.
• W3206788435 creator A5053525786 @default.
• W3206788435 creator A5064986096 @default.
• W3206788435 creator A5069483443 @default.
• W3206788435 creator A5079410902 @default.
• W3206788435 creator A5081043627 @default.
• W3206788435 creator A5084489599 @default.
• W3206788435 creator A5085805106 @default.
• W3206788435 date "2022-02-01" @default.
• W3206788435 modified "2023-09-27" @default.
• W3206788435 title "Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug–Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization" @default.
• W3206788435 cites W1501386419 @default.
• W3206788435 cites W1509849157 @default.
• W3206788435 cites W1885435857 @default.
• W3206788435 cites W1923203539 @default.
• W3206788435 cites W1984854386 @default.
• W3206788435 cites W1984906148 @default.
• W3206788435 cites W2004627112 @default.
• W3206788435 cites W2008931469 @default.
• W3206788435 cites W2012122843 @default.
• W3206788435 cites W2076762555 @default.
• W3206788435 cites W2085071459 @default.
• W3206788435 cites W2094866624 @default.
• W3206788435 cites W2098968578 @default.
• W3206788435 cites W2101001598 @default.
• W3206788435 cites W2105880697 @default.
• W3206788435 cites W2110052844 @default.
• W3206788435 cites W2112846968 @default.
• W3206788435 cites W2121954044 @default.
• W3206788435 cites W2145029470 @default.
• W3206788435 cites W2156959293 @default.
• W3206788435 cites W2168515303 @default.
• W3206788435 cites W2202379982 @default.
• W3206788435 cites W2336979047 @default.
• W3206788435 cites W2519193275 @default.
• W3206788435 cites W2535606296 @default.
• W3206788435 cites W2579496387 @default.
• W3206788435 cites W2618783565 @default.
• W3206788435 cites W2765477066 @default.
• W3206788435 cites W2804921717 @default.
• W3206788435 cites W2891218618 @default.
• W3206788435 cites W2891631842 @default.
• W3206788435 cites W2900203670 @default.
• W3206788435 cites W2949611717 @default.
• W3206788435 cites W2972906730 @default.
• W3206788435 cites W2991620982 @default.
• W3206788435 cites W3009076370 @default.
• W3206788435 cites W3010193169 @default.
• W3206788435 cites W3013351791 @default.
• W3206788435 cites W3034146395 @default.
• W3206788435 cites W3048182136 @default.
• W3206788435 cites W3110082941 @default.
• W3206788435 cites W3111053716 @default.
• W3206788435 cites W3112742104 @default.
• W3206788435 cites W3124764718 @default.
• W3206788435 cites W4386008406 @default.
• W3206788435 doi "https://doi.org/10.1016/j.jaip.2021.09.050" @default.
• W3206788435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34678497" @default.
• W3206788435 hasPublicationYear "2022" @default.
• W3206788435 type Work @default.
• W3206788435 sameAs 3206788435 @default.
• W3206788435 citedByCount "7" @default.
• W3206788435 countsByYear W32067884352022 @default.
• W3206788435 countsByYear W32067884352023 @default.
• W3206788435 crossrefType "journal-article" @default.
• W3206788435 hasAuthorship W3206788435A5001448895 @default.
• W3206788435 hasAuthorship W3206788435A5013554446 @default.
• W3206788435 hasAuthorship W3206788435A5017906399 @default.
• W3206788435 hasAuthorship W3206788435A5025436509 @default.
• W3206788435 hasAuthorship W3206788435A5027654158 @default.
• W3206788435 hasAuthorship W3206788435A5053402932 @default.
• W3206788435 hasAuthorship W3206788435A5053525786 @default.
• W3206788435 hasAuthorship W3206788435A5064986096 @default.
• W3206788435 hasAuthorship W3206788435A5069483443 @default.
• W3206788435 hasAuthorship W3206788435A5079410902 @default.
• W3206788435 hasAuthorship W3206788435A5081043627 @default.
• W3206788435 hasAuthorship W3206788435A5084489599 @default.
• W3206788435 hasAuthorship W3206788435A5085805106 @default.
• W3206788435 hasConcept C126322002 @default.
• W3206788435 hasConcept C141105273 @default.
• W3206788435 hasConcept C159654299 @default.
• W3206788435 hasConcept C197934379 @default.
• W3206788435 hasConcept C203014093 @default.
• W3206788435 hasConcept C207480886 @default.
• W3206788435 hasConcept C2776042228 @default.
• W3206788435 hasConcept C2776217527 @default.
• W3206788435 hasConcept C2777628954 @default.
• W3206788435 hasConcept C2778375690 @default.
• W3206788435 hasConcept C2778564945 @default.
• W3206788435 hasConcept C2781390199 @default.
• W3206788435 hasConcept C71924100 @default.

• next